US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Altech Digitial Co.

Volume:- -

Turnover:- -

Market Cap:- -

PE:- -

High:- -

Open:- -

Low:- -

Close:- -

52wk High:- -

52wk Low:- -

Shares:29.50M

Float Shares:1.50M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

ROE:259.58%

ROA:48.64%

PB:0.00

PE(LYR):- -

Loading ...

Overview Company News Filings

Altimmune Announces Pricing of $75 Million Registered Direct Offering of Common Stock

Ampol Lifts Refining Margins and Flags Strong 2025 Earnings

While institutions invested in Ampol Limited (ASX:ALD) benefited from last week's 3.4% gain, retail investors stood to gain the most

Simply Wall St.

Ampol Faces Phase 2 ACCC Review of EG Australia Acquisition

Hong Kong-Based IT Services Firm Altech Digital (ALD.US) Withdraws $6 Million US IPO Plan

Investors Aren't Buying Ampol Limited's (ASX:ALD) Revenues

Simply Wall St.

Press Release: Altimmune Announces CEO Transition and Succession Plan

Ampol Limited Updates Director’s Interest Notice Amid Oversight

Press Release: Poxel Reports Revenue for the Third Quarter 2025

Altimmune Announces Publication of IMPACT Phase 2b Trial Data in The Lancet and Concurrent Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2025

Returns Are Gaining Momentum At Ampol (ASX:ALD)

Simply Wall St.

Altimmune Presents AI-Based Analysis of Liver Fibrosis Reduction from IMPACT Phase 2b Trial of Pemvidutide in MASH in Late-breaking Poster at AASLD The Liver Meeting® 2025

Altimmune Announces Early Completion of Enrollment in RECLAIM Phase 2 Trial Evaluating Pemvidutide in Alcohol Use Disorder

Altimmune to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025

Adisyn Ltd Advances Graphene Technology with New ALD System Installation

Altimmune’s RESTORE TRIAL: A Promising Step in ALD Treatment

Altimmune to Present Phase 2b IMPACT Data on Pemvidutide in MASH in Late-Breaking Oral Podium Presentation and Late-Breaking Poster at AASLD The Liver Meeting® 2025

Ampol (ASX:ALD) Takes On Some Risk With Its Use Of Debt

Simply Wall St.

1 Super Semiconductor Stock (Besides Nvidia or Broadcom) to Buy Hand Over Fist

Press Release: Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ALD/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ALD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ALD\",,,,,undefined,":{"symbol":"ALD","market":"US","secType":"STK","nameCN":"Altech Digitial Co.","latestPrice":0,"timestamp":1770411600000,"preClose":0,"halted":9,"volume":0,"delay":0,"floatShares":1500000,"shares":29500000,"eps":0,"marketStatus":"Market Closed","change":0,"latestTime":"02-06 16:00:00 EST","open":0,"high":0,"low":0,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770627600000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1767070800000,"exchange":"NASDAQ","adjPreClose":0,"sharesOutstanding":400000,"nav":44.492139,"aum":17756473.36,"bidAskSpread":0,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ALD\",,,,,undefined,":{"symbol":"ALD","floatShares":1500000,"roa":"48.64%","roe":"259.58%","lyrEps":0,"shares":29500000,"dividePrice":0,"high":0,"amplitude":0,"preClose":0,"low":0,"week52Low":0,"pbRate":"0.00","psRate":"0.00","week52High":0,"institutionHeld":0,"latestPrice":0,"eps":0,"divideRate":0,"volume":0,"delay":0,"ttmEps":0,"open":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ALD\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ALD\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ALD\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ALD\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2606768781","title":"Altimmune Announces Pricing of $75 Million Registered Direct Offering of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2606768781","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606768781?lang=en_us&edition=fundamental","pubTime":"2026-01-28 10:25","pubTimestamp":1769567100,"startTime":"0","endTime":"0","summary":"GAITHERSBURG, Md., Jan.  27, 2026  (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, announce","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/28/3227158/0/en/Altimmune-Announces-Pricing-of-75-Million-Registered-Direct-Offering-of-Common-Stock.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALD"],"gpt_icon":0},{"id":"2606756971","title":"Ampol Lifts Refining Margins and Flags Strong 2025 Earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2606756971","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606756971?lang=en_us&edition=fundamental","pubTime":"2026-01-28 06:37","pubTimestamp":1769553479,"startTime":"0","endTime":"0","summary":"An update from Ampol Limited ( ($AU:ALD) ) is now available. Ampol reported a sharp improvement in refining economics in the fourth quarter of 2025...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ampol-lifts-refining-margins-and-flags-strong-2025-earnings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ampol-lifts-refining-margins-and-flags-strong-2025-earnings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALD"],"gpt_icon":0},{"id":"2605286978","title":"While institutions invested in Ampol Limited (ASX:ALD) benefited from last week's 3.4% gain, retail investors stood to gain the most","url":"https://stock-news.laohu8.com/highlight/detail?id=2605286978","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605286978?lang=en_us&edition=fundamental","pubTime":"2026-01-24 04:02","pubTimestamp":1769198523,"startTime":"0","endTime":"0","summary":"Key Insights The considerable ownership by retail investors in Ampol indicates that they collectively have a greater...","market":"us","thumbnail":"https://images.simplywall.st/asset/company-cover/877088-main-header/1590544527052","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/877088-main-header/1590544527052"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/energy/asx-ald/ampol-shares/news/while-institutions-invested-in-ampol-limited-asxald-benefite","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/energy/asx-ald/ampol-shares/news/while-institutions-invested-in-ampol-limited-asxald-benefite","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7065","ALD","ALD.AU"],"gpt_icon":0},{"id":"2605140457","title":"Ampol Faces Phase 2 ACCC Review of EG Australia Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2605140457","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605140457?lang=en_us&edition=fundamental","pubTime":"2026-01-21 07:49","pubTimestamp":1768952942,"startTime":"0","endTime":"0","summary":"Ampol Limited ( ($AU:ALD) ) has provided an update. Ampol has confirmed that the Australian Competition and Consumer Commission will move to a Phas...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ampol-faces-phase-2-accc-review-of-eg-australia-acquisition?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ampol-faces-phase-2-accc-review-of-eg-australia-acquisition?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00B19Z3581.USD","BK4019","LU0077335932.USD","EG","IE00B19Z3B42.SGD","LU0211331839.USD","ALD","BK4585","IE0002270589.USD","BK4588"],"gpt_icon":0},{"id":"1165950877","title":"Hong Kong-Based IT Services Firm Altech Digital (ALD.US) Withdraws $6 Million US IPO Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=1165950877","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165950877?lang=en_us&edition=fundamental","pubTime":"2026-01-07 15:13","pubTimestamp":1767770015,"startTime":"0","endTime":"0","summary":"Altech Digital (ALD.US), a Hong Kong-based provider of IT system development, maintenance, and consulting services, withdrew its initial public offering plan on Tuesday. The company had initially...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALD"],"gpt_icon":0},{"id":"2588008555","title":"Investors Aren't Buying Ampol Limited's (ASX:ALD) Revenues","url":"https://stock-news.laohu8.com/highlight/detail?id=2588008555","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588008555?lang=en_us&edition=fundamental","pubTime":"2025-12-04 05:45","pubTimestamp":1764798353,"startTime":"0","endTime":"0","summary":"Ampol Limited's ( ASX:ALD ) price-to-sales (or \"P/S\") ratio of 0.2x might make it look like a strong buy right now...","market":"nz","thumbnail":"https://images.simplywall.st/asset/company-cover/877088-main-header/1590544527052","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/877088-main-header/1590544527052"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/energy/asx-ald/ampol-shares/news/investors-arent-buying-ampol-limiteds-asxald-revenues-1","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/energy/asx-ald/ampol-shares/news/investors-arent-buying-ampol-limiteds-asxald-revenues-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ISBC","ALD.AU","ALD"],"gpt_icon":0},{"id":"2588727863","title":"Press Release: Altimmune Announces CEO Transition and Succession Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2588727863","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588727863?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:30","pubTimestamp":1764592200,"startTime":"0","endTime":"0","summary":"Jerry Durso, accomplished industry leader, to succeed Vipin Garg, Ph.D. as Chief Executive Officer. Transition follows seven years of strong leadership by Dr. Garg. GAITHERSBURG, Md., Dec. 01, 2025  -- Altimmune, Inc. , a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and metabolic diseases, today announced a CEO succession plan under which Vipin Garg, Ph.D. will step down as the Company's President and Chief Executive Officer effective January 1, 2026. Altimmune's Chairman of the Board, Jerry Durso, will assume the role of President and Chief Executive Officer and retain his position as Chairman. To facilitate a smooth transition, Dr. Garg will serve as an advisor to the Company through June 30, 2026.\"I am very excited to step into the role of CEO as Altimmune embarks on its next phase of growth and prepares to transition to a late-stage clinical company looking toward commercialization. I see significant potential for pemvidutide t","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU1878469433.USD","ALT","ALD","BK4599"],"gpt_icon":0},{"id":"2584718581","title":"Ampol Limited Updates Director’s Interest Notice Amid Oversight","url":"https://stock-news.laohu8.com/highlight/detail?id=2584718581","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584718581?lang=en_us&edition=fundamental","pubTime":"2025-11-20 15:25","pubTimestamp":1763623558,"startTime":"0","endTime":"0","summary":"Ampol Limited ( ($AU:ALD) ) has provided an announcement. Ampol Limited announced a change in the director’s interest notice for Guy Templeton, hig...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ampol-limited-updates-directors-interest-notice-amid-oversight?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ampol-limited-updates-directors-interest-notice-amid-oversight?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALD"],"gpt_icon":0},{"id":"2583635518","title":"Press Release: Poxel Reports Revenue for the Third Quarter 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2583635518","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583635518?lang=en_us&edition=fundamental","pubTime":"2025-11-14 01:47","pubTimestamp":1763056020,"startTime":"0","endTime":"0","summary":" compared to the previous quarter and up 40% compared to. --  Gross TWYMEEG for Sumitomo Pharma amounted to JPY 5 billion for the. first half ended September 30, supporting its full-year forecast of JPY. represent a 47% increase compared to fiscal year 2024 sales. Nicolas Trouche, Chief Executive Officer of Poxel, states: \"Dear shareholders, as you know, Poxel is in a very difficult situation due to its financial circumstances, which has led us to seek protection from the Economic Affairs Court under a reorganization proceedings. Nevertheless, the once again encouraging sales figures for TWYMEEG in Japan show that the company has, with Imeglimin, a high-quality asset with strong growth potential. The management team, alongside Yves Decadt, is therefore redoubling its efforts to promote this asset in the rest of the world. These efforts also focus on promoting the other molecules in the portfolio.\". TWYMEEG sales for the quarter ended 30 September 2025. --  Based on these forecasts for ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALD","R","IE00B2B36J28.USD","IE000M9KFDE8.USD","BK4585","LU1934455194.USD","MRK","LU0965509010.AUD","SG9999014575.USD","BK4232","LU0208291251.USD","LU0861579265.USD","SG9999002224.SGD","SG9999014542.SGD","LU1069347547.HKD","LU1116320737.USD","LU1066051811.HKD","IE00BJJMRZ35.SGD","LU1066051225.USD","LU1061106388.HKD","LU2361044949.HKD","IE00BLSP4452.SGD","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","LU0289739699.SGD","BK4533","LU2106854487.HKD","LU1035773651.USD","LU1941712264.USD","LU1037948541.HKD","LU0238689110.USD","IE00BJT1NW94.SGD","LU0098860793.USD","SG9999002232.USD","IE00B1BXHZ80.USD","LU0211331839.USD","LU2112291526.USD","SG9999013999.USD","LU0006306889.USD","LU0965509283.SGD","IE00BBT3K403.USD","LU2461242641.AUD","LU0265550946.USD","LU1699723380.USD","LU2468319806.SGD","LU1571399168.USD","LU2361044865.SGD","SG9999015358.SGD","IE0002141913.USD"],"gpt_icon":0},{"id":"2582362610","title":"Altimmune Announces Publication of IMPACT Phase 2b Trial Data in The Lancet and Concurrent Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2582362610","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582362610?lang=en_us&edition=fundamental","pubTime":"2025-11-11 21:51","pubTimestamp":1762869060,"startTime":"0","endTime":"0","summary":"24-week data demonstrated significant MASH resolution and weight loss, and strong evidence of anti-fibrotic activity with a favorable tolerability profile Significant improvements observed in secondar","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/11/3185445/0/en/Altimmune-Announces-Publication-of-IMPACT-Phase-2b-Trial-Data-in-The-Lancet-and-Concurrent-Late-Breaking-Oral-Presentation-at-AASLD-The-Liver-Meeting-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0072462343.USD","LU0175139822.USD","IE0001KFT4U8.USD","SG9999005177.SGD","SG9999013486.USD","LU2543165471.USD","BK4535","SG9999014492.USD","LU2065170008.USD","LU2045819591.USD","LU2360107671.USD","SGXZ58947870.SGD","SG9999002620.SGD","SG9999002679.SGD","LU2125910500.SGD","LU0345775950.USD","SG9999006266.SGD","LU0823039010.USD","BK4554","LU0532188223.SGD","LU1770036033.HKD","LU0251143029.SGD","LU0823038988.USD","BK4503","LU1839390173.USD","LU0289960550.SGD","LU1861220207.SGD","SG9999014484.SGD","BK4220","LU0441851309.USD","LU0499858602.USD","BK4548","LU0499858438.USD","LU2125910849.SGD","SG9999002414.USD","IE00BD6J9T35.USD","LU2065169927.USD","LU1861217088.USD","LU1242518931.SGD","LU2238330802.EUR","SG9999004360.SGD","LU2177674079.SGD","BK4581","BK4566","LU1048588211.SGD","LU0979878070.USD","LU0589944569.HKD","ALD"],"gpt_icon":1},{"id":"2581861856","title":"Returns Are Gaining Momentum At Ampol (ASX:ALD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2581861856","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581861856?lang=en_us&edition=fundamental","pubTime":"2025-11-08 05:56","pubTimestamp":1762552608,"startTime":"0","endTime":"0","summary":"If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...","market":"nz","thumbnail":"https://images.simplywall.st/asset/company-cover/877088-main-header/1590544527052","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/877088-main-header/1590544527052"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/energy/asx-ald/ampol-shares/news/returns-are-gaining-momentum-at-ampol-asxald","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/energy/asx-ald/ampol-shares/news/returns-are-gaining-momentum-at-ampol-asxald","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ALD.AU","ALD","BK7065","EBIT"],"gpt_icon":0},{"id":"2581488667","title":"Altimmune Presents AI-Based Analysis of Liver Fibrosis Reduction from IMPACT Phase 2b Trial of Pemvidutide in MASH in Late-breaking Poster at AASLD The Liver Meeting® 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2581488667","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581488667?lang=en_us&edition=fundamental","pubTime":"2025-11-07 21:05","pubTimestamp":1762520700,"startTime":"0","endTime":"0","summary":"AI-based digital pathology analysis provides high-resolution quantification of hepatic fibrosis and objective measurement of fibrosis improvement Pemvidutide demonstrated significant reductions in liv","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/07/3183618/0/en/Altimmune-Presents-AI-Based-Analysis-of-Liver-Fibrosis-Reduction-from-IMPACT-Phase-2b-Trial-of-Pemvidutide-in-MASH-in-Late-breaking-Poster-at-AASLD-The-Liver-Meeting-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4543","ALD","BK4585","BK4587","BK4588","BK4023","BK4528","BK4551","AI"],"gpt_icon":0},{"id":"2580087290","title":"Altimmune Announces Early Completion of Enrollment in RECLAIM Phase 2 Trial Evaluating Pemvidutide in Alcohol Use Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2580087290","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580087290?lang=en_us&edition=fundamental","pubTime":"2025-11-03 20:30","pubTimestamp":1762173000,"startTime":"0","endTime":"0","summary":"Enrollment completed ahead of schedule, underscoring strong interest from patient community in a potential new therapeutic option On track to complete the 24-week treatment period and announce topline","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/03/3179153/0/en/Altimmune-Announces-Early-Completion-of-Enrollment-in-RECLAIM-Phase-2-Trial-Evaluating-Pemvidutide-in-Alcohol-Use-Disorder.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALD"],"gpt_icon":0},{"id":"2579433491","title":"Altimmune to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2579433491","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579433491?lang=en_us&edition=fundamental","pubTime":"2025-10-30 19:30","pubTimestamp":1761823800,"startTime":"0","endTime":"0","summary":"GAITHERSBURG, Md., Oct.  30, 2025  (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiome","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/30/3177270/0/en/Altimmune-to-Report-Third-Quarter-2025-Financial-Results-and-Provide-Business-Update-on-November-6-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALD"],"gpt_icon":0},{"id":"2579321931","title":"Adisyn Ltd Advances Graphene Technology with New ALD System Installation","url":"https://stock-news.laohu8.com/highlight/detail?id=2579321931","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579321931?lang=en_us&edition=fundamental","pubTime":"2025-10-30 05:38","pubTimestamp":1761773910,"startTime":"0","endTime":"0","summary":"DC Two Ltd. ( ($AU:AI1) ) has issued an announcement. Adisyn Ltd has reported significant progress in its quarterly activities, highlighting a stro...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/adisyn-ltd-advances-graphene-technology-with-new-ald-system-installation?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/adisyn-ltd-advances-graphene-technology-with-new-ald-system-installation?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALD"],"gpt_icon":0},{"id":"2578262751","title":"Altimmune’s RESTORE TRIAL: A Promising Step in ALD Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2578262751","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578262751?lang=en_us&edition=fundamental","pubTime":"2025-10-28 02:55","pubTimestamp":1761591355,"startTime":"0","endTime":"0","summary":"Altimmune (($ALT)) announced an update on their ongoing clinical study. Study Overview: The RESTORE TRIAL is a Phase 2 study conducted by Altimmune...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/altimmunes-restore-trial-a-promising-step-in-ald-treatment-3?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/altimmunes-restore-trial-a-promising-step-in-ald-treatment-3?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALD"],"gpt_icon":0},{"id":"2576856036","title":"Altimmune to Present Phase 2b IMPACT Data on Pemvidutide in MASH in Late-Breaking Oral Podium Presentation and Late-Breaking Poster at AASLD The Liver Meeting® 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2576856036","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576856036?lang=en_us&edition=fundamental","pubTime":"2025-10-20 19:30","pubTimestamp":1760959800,"startTime":"0","endTime":"0","summary":"Oral presentation to highlight 24-week efficacy and safety data Poster to feature results of AI-based analyses of liver fibrosis reduction GAITHERSBURG, Md., Oct.  20, 2025  (GLOBE NEWSWIRE) -- Altimm","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/20/3169260/0/en/Altimmune-to-Present-Phase-2b-IMPACT-Data-on-Pemvidutide-in-MASH-in-Late-Breaking-Oral-Podium-Presentation-and-Late-Breaking-Poster-at-AASLD-The-Liver-Meeting-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALD"],"gpt_icon":0},{"id":"2575976839","title":"Ampol (ASX:ALD) Takes On Some Risk With Its Use Of Debt","url":"https://stock-news.laohu8.com/highlight/detail?id=2575976839","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575976839?lang=en_us&edition=fundamental","pubTime":"2025-10-16 04:00","pubTimestamp":1760558404,"startTime":"0","endTime":"0","summary":"The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...","market":"us","thumbnail":"https://images.simplywall.st/asset/company-cover/877088-main-header/1590544527052","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/877088-main-header/1590544527052"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/energy/asx-ald/ampol-shares/news/ampol-asxald-takes-on-some-risk-with-its-use-of-debt-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/energy/asx-ald/ampol-shares/news/ampol-asxald-takes-on-some-risk-with-its-use-of-debt-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ALD.AU","EBIT","BK7065","ALD"],"gpt_icon":0},{"id":"2572532164","title":"1 Super Semiconductor Stock (Besides Nvidia or Broadcom) to Buy Hand Over Fist","url":"https://stock-news.laohu8.com/highlight/detail?id=2572532164","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572532164?lang=en_us&edition=fundamental","pubTime":"2025-10-01 21:45","pubTimestamp":1759326300,"startTime":"0","endTime":"0","summary":"Investors should start looking beyond prominent names in the AI infrastructure space.","market":"nz","thumbnail":"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F835396%2Fanalyst_analyzing_stock_charts_on_desktop_and_laptop.jpg&op=resize&w=165&h=104","type":0,"news_type":0,"thumbnails":["https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F835396%2Fanalyst_analyzing_stock_charts_on_desktop_and_laptop.jpg&op=resize&w=165&h=104"],"rights":{"source":"fool_stock","url":"https://www.fool.com/investing/2025/10/01/1-semiconductor-stock-besides-nvidia-or-broadcom/","rn_cache_url":null,"customStyle":"","selectors":".main-contain, #article-page","filters":"#sticky-wrapper, .navigation, .article-page-end, .foot, .author-tagline, .author-inline, .footer, .soc-share, .wysiwyg, .related-content","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/10/01/1-semiconductor-stock-besides-nvidia-or-broadcom/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["NVD3.UK","LU0557290698.USD","LU1861127337.USD","NVDD","GAA","NVDY","LU0127658192.USD","NVDS.UK","NVDX","IE00BQXX3C00.GBP","NVD","LU2290526834.HKD","LU2433249047.HKD","SOXX","LU0276348264.USD","LU1852331112.SGD","NVIW.SI","LU1815336760.USD","SAM","AVGOP","LU1066051498.USD","LU2063271972.USD","LU1037948897.HKD","2NVD.UK","3NVD.UK","NVDS","ALD","HK0000306685.HKD","LU2108987350.USD","NVD2.UK","LU1935043536.SGD","SNVD.UK","SMH","LU1923622291.USD","LU0345768153.USD","LU1989772923.USD","LU2244417387.USD","LU0265550359.USD","LRCX","NVDU","IE00BQXX3F31.USD","LU1242518931.SGD","LU2213496289.HKD","LU1989772840.SGD"],"gpt_icon":1},{"id":"2571380575","title":"Press Release: Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide","url":"https://stock-news.laohu8.com/highlight/detail?id=2571380575","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571380575?lang=en_us&edition=fundamental","pubTime":"2025-09-29 19:30","pubTimestamp":1759145400,"startTime":"0","endTime":"0","summary":"Seasoned clinical leader to oversee Phase 3 development of pemvidutide in MASH. Dr. Arbet-Engels has led late-stage development, regulatory approvals and commercial launches for multiple successful franchises. \"We are thrilled to welcome Christophe to the team at this crucial juncture in Altimmune's evolution,\" said Vipin K. Garg, Ph.D., President and CEO of Altimmune. \"He brings a wealth of experience across mid- and late-stage clinical development, regulatory approvals and commercial launches that will be invaluable as we continue to advance pemvidutide and work toward our mission of establishing a new standard of care in the treatment of hepato-metabolic disorders. On behalf of the executive team and Board of Directors, I would also like to thank Scott for his instrumental contributions over the last six years. His oversight of the pemvidutide program through multiple INDs and clinical trials has positioned us well as we prepare to enter Phase 3 development in MASH.\". Dr. Arbet-Enge","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","ALT","BK4599","BK4232","ALD","R","LU1878469433.USD","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":28,"code":"91000000","status":"200"}]}}